Subject: Nature Reviews Drug Discovery Table of Contents Vol 5 Issue 10 October 2006

From: "Nature Reviews Drug Discovery Alert"<[email-masked]>
Date: Fri, 13 Oct 2006 06:56:11 -0400 (EDT)

TABLE OF CONTENTS

October 2006 Volume 5 Number 10

This alert is sponsored by Tripos

Impact Factor 18.775 *

| Subscribe to Nature Reviews Drug Discovery
| Recommend to your library

In this issue
News Analysis
Research Highlights
Perspectives
Reviews

Also this month
Featured article:
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm, Christopher Carter, Mark Lynch, Timothy Lowinger, Jacques Dumas, Roger A. Smith, Brian Schwartz, Ronit Simantov and Susan Kelley

Ensure your institution has access to Nature Reviews Drug Discovery, recommend a subscription to your library today

In This Issue
p801 | 10.1038/nrd2166 Full Text

Editorial: A tale of two drugs
p803 | 10.1038/nrd2167Abstract | Full Text | PDF

NEWS ANALYSIS

Top

New bill aims to reform US patent system
Simon Frantz
p805 | 10.1038/nrd2168
Several recommendations will have significant impact on pharmaceutical and biotechnology industries

HIV prevention trials in danger of grinding to a standstill
Erika Check
p806 | 10.1038/nrd2169
Researchers unable to get meaningful data on effectiveness of new treatments

Origins of ecstasy an urban myth
David Adam
p806 | 10.1038/nrd2172
Clubber's drug was not originally developed to help German army

NEWS IN BRIEF
News in brief
p808 | 10.1038/nrd2170

PATENT WATCH
Ariad's claims to NF-[kappa]B pathway rejected | Apotex appeal Plavix injunction | Oxybutynin too 'obvious' | Interleukin-1 receptor inhibition
p810 | 10.1038/nrd2171

CAREER PATH
Career path: William R. Keller
Sabine Louet
p812 | 10.1038/nrd2158

FROM THE ANALYST'S COUCH
Life after statin patent expiries
Jane Kidd
p813 | 10.1038/nrd2156

FRESH FROM THE PIPELINE
Ranibizumab
Raja Narayanan, Baruch D. Kuppermann, Carole Jones & Peter Kirkpatrick
p815 | 10.1038/nrd2157
Ranibizumab (Lucentis; Genentech), a humanized monoclonal antibody fragment that binds to vascular endothelial growth factor, was approved by the US FDA in June 2006 for the treatment of patients with neovascular age-related macular degeneration.

RESEARCH HIGHLIGHTS

Top

Psychiatric disorders: ProTREKtion against depression
p817 | 10.1038/nrd2162

Angiogenesis: Familiar faces and new connections
p818 | 10.1038/nrd2160

Anticancer drugs: Activating the executioner
p818 | 10.1038/nrd2164

Biomarkers: Signatures of schizophrenia
p819 | 10.1038/nrd2161

Lung cancer: Strengthening the link to adenosine
p820 | 10.1038/nrd2163

IN BRIEF
High-throughput screening | Therapeutic angiogenesis | Metabolic disorders | Cancer
p820 | 10.1038/nrd2165

PERSPECTIVES

Top

OPINION
Drugs, their targets and the nature and number of drug targets
Peter Imming, Christian Sinning & Achim Meyer
p821 | 10.1038/nrd2132
What constitutes a drug target? Imming and colleagues consider this question, and by classifying known drug substances on the basis of the discussed principles, provide an estimation of the total number of current drug targets.
Abstract | Full Text | PDF

Advertisement

Advertisement

REVIEWS

Top

CASE HISTORY
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
p835 | 10.1038/nrd2130
In December 2005, sorafenib became the first new treatment to be approved for advanced renal cancer in more than a decade. Wilhelm and colleagues provide the history of this drug, which inhibits several kinases involved in tumour signalling and angiogenesis.
Abstract | Full Text | PDF

Novel pharmacological targets for the treatment of Parkinson's disease
Anthony H. V. Schapira et al.
p845 | 10.1038/nrd2087
Schapira and colleagues describe recent advances in the development of novel doperminergic and non-doperminergic drugs for the treatment of Parkinson's disease and related motor complications.
Abstract | Full Text | PDF

CASE HISTORY
Discovery and development of clofarabine: a nucleoside analogue for treating cancer
Peter L. Bonate et al.
p855 | 10.1038/nrd2055
Despite considerable progress in the treatment of paediatric leukaemias, a major need still exists for therapies for patients who relapse. Bonate and colleagues describe the discovery and development of the nucleoside analogue clofarabine, which is the first such drug approved for paediatric leukaemia in more than a decade, and the first to receive approval for paediatric use before adult use.
Abstract | Full Text | PDF

Signalling platforms that modulate the inflammatory response: new targets for drug development
Christopher. A. McCulloch, Gregory P. Downey & Hani El-Gabalawy
p864 | 10.1038/nrd2109
Inflammatory diseases of lung, liver, heart, joints and periodontium have high prevalence, but many current treatments have limited efficacy and are expensive. McCulloch and colleagues consider new anti-inflammatory drug targets based on the clustering of interleukin- 1 receptors into multi-protein aggregates associated with cell adhesions.
Abstract | Full Text | PDF

Nature Biotechnology is proud to present in October 2006 a special reprint supplement on the MicroArray Quality Control consortium sponsored by FDA, EPA, NCI and Agilent. The study provides a clear and statistically sound picture of reproducibility and reliability of seven different microarray gene expression analysis platforms. For more information visit: www.nature.com/naturebiotechnology

| |

| | Director | | Neuroscience|Drug Discovery|Infectious Diseases|Biochemistry|Biophysics| | | Merckboston | | Boston, MA |
| | |

Commissioning Editor

Biomedical Sciences|Publishing
|Life Sciences|Computer Science|Bioinformatics|

The Future
Science Group

London, United Kingdom

| | |

GI Scientist

Pharmacology|Drug Discovery|Pathology|Physiology
|Biological Sciences|

GlaxoSmith
Kline

Cork, Ireland

| | |

Assistant Director

Drug Discovery|Pathology|Molecular Biology
|Biological Sciences|Medical Sciences|

SERVIER

Paris, France

| | |

More Naturejobs

| |
| | | | | |

| |

Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the 2005 Natureevents Directory are now live. The digital version is available here.

| |

More Nature Products

More Nature Events

| |

*Journal Citation Reports, Thomson, 2005

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston